The use of galantamine HBr [hydrobromide] (Reminyl) in electroconvulsive therapy: Impact on mood and cognitive functioning.

Trial Profile

The use of galantamine HBr [hydrobromide] (Reminyl) in electroconvulsive therapy: Impact on mood and cognitive functioning.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2012

At a glance

  • Drugs Galantamine (Primary)
  • Indications Cognition disorders; Mood disorders
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 12 Aug 2009 Actual patient number changed from 39 to 44 as reported by ClinicalTrials.gov.
    • 12 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 May 2009 Results presented at APA 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top